Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Melissa A Maddie"'
Publikováno v:
ASN Neuro, Vol 1 (2009)
Microvascular dysfunction, loss of vascular support, ischaemia and sub-acute vascular instability in surviving blood vessels contribute to secondary injury following SCI (spinal cord injury). Neither the precise temporal profile of the cellular dynam
Externí odkaz:
https://doaj.org/article/b42cfd3ec5b94a3ca8a44722306a48aa
Autor:
Paul M. Wehn, Song Yang, Jonas A. Grina, James P. Rizzi, Stephen T. Schlachter, Bin Wang, Rui Xu, Hanbiao Yang, Xinlin Du, Guangzhou Han, Keshi Wang, Robert M. Czerwinski, Emily L. Ged, Heli Huang, Megan M. Halfmann, Melissa A. Maddie, Emily R. Morton, Sarah R. Olive, Huiling Tan, Shanhai Xie, John A. Josey, Eli M. Wallace
Pharmacokinetic properties of our first-generation HIF-2α antagonist PT2385, including modest solubility, resulted in a high recommended phase 2 dose (RP2D) of 800 mg BID and motivated the pursuit of novel scaffolds which could improve solubility an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df873b27c3e83d093d39f5958023934e
https://doi.org/10.21203/rs.3.rs-2753648/v1
https://doi.org/10.21203/rs.3.rs-2753648/v1
Autor:
John A. Josey, Hanbiao Yang, Rui Xu, Shanhai Xie, Keshi Wang, Bin Wang, Huiling Tan, Stephen T. Schlachter, Sarah R. Olive, Melissa A. Maddie, Megan M. Halfmann, Jonas A. Grina, Barry S. Goggin, Darryl D. Dixon, Robert M. Czerwinski, Tzuling Cheng, Xinlin Du, Zhaodan Cao, Paul M. Wehn, Guangzhou Han, James P. Rizzi, Eli M. Wallace
Supplementary method includes detailed experimental procedure for the synthesis of PT2385. Supplementary Figures 1-7 - Lack of cytotoxicity of PT2385 in cultured 786-O and A498 cells (1); PT2385 pharmacokinetics in CD-1 mice (2); Inhibition of HIF-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76ba58b87702663a6c4d7ea731902dd9
https://doi.org/10.1158/0008-5472.22411674.v1
https://doi.org/10.1158/0008-5472.22411674.v1
Autor:
John A. Josey, Hanbiao Yang, Rui Xu, Shanhai Xie, Keshi Wang, Bin Wang, Huiling Tan, Stephen T. Schlachter, Sarah R. Olive, Melissa A. Maddie, Megan M. Halfmann, Jonas A. Grina, Barry S. Goggin, Darryl D. Dixon, Robert M. Czerwinski, Tzuling Cheng, Xinlin Du, Zhaodan Cao, Paul M. Wehn, Guangzhou Han, James P. Rizzi, Eli M. Wallace
More than 90% of clear cell renal cell carcinomas (ccRCC) exhibit inactivation of the von Hippel–Lindau (pVHL) tumor suppressor, establishing it as the major underlying cause of this malignancy. pVHL inactivation results in stabilization of the hyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cb681633f0b5416aa695f9339844dfb
https://doi.org/10.1158/0008-5472.c.6508272.v1
https://doi.org/10.1158/0008-5472.c.6508272.v1
Autor:
John A. Josey, Zhaodan Cao, Tai Wong, Megan M. Halfmann, Heli Huang, Barry Goggin, Robert M. Czerwinski, Hanbiao Yang, Paul M. Wehn, Bin Wang, Shanhai Xie, Sarah R. Olive, Huiling Tan, Eli M. Wallace, Darryl D. Dixon, Melissa A. Maddie, Xinlin Du, Rui Xu, Stephen T. Schlachter, James P. Rizzi, Emily L. Morton, Tzuling Cheng, Jonas Grina, Keshi Wang, Guangzhou Han
Publikováno v:
Journal of Medicinal Chemistry. 61:9691-9721
HIF-2α, a member of the HIF family of transcription factors, is a key oncogenic driver in cancers such as clear cell renal cell carcinoma (ccRCC). A signature feature of these cancers is the overaccumulation of HIF-2α protein, often by inactivation
Autor:
Paul M, Wehn, James P, Rizzi, Darryl D, Dixon, Jonas A, Grina, Stephen T, Schlachter, Bin, Wang, Rui, Xu, Hanbiao, Yang, Xinlin, Du, Guangzhou, Han, Keshi, Wang, Zhaodan, Cao, Tzuling, Cheng, Robert M, Czerwinski, Barry S, Goggin, Heli, Huang, Megan M, Halfmann, Melissa A, Maddie, Emily L, Morton, Sarah R, Olive, Huiling, Tan, Shanhai, Xie, Tai, Wong, John A, Josey, Eli M, Wallace
Publikováno v:
Journal of medicinal chemistry. 61(21)
HIF-2α, a member of the HIF family of transcription factors, is a key oncogenic driver in cancers such as clear cell renal cell carcinoma (ccRCC). A signature feature of these cancers is the overaccumulation of HIF-2α protein, often by inactivation
Autor:
Melissa A. Maddie, Rui Xu, Guangzhou Han, Paul M. Wehn, Sarah R. Olive, Huiling Tan, Eli M. Wallace, Zhaodan Cao, Keshi Wang, Bin Wang, Megan M. Halfmann, Jonas Grina, Robert M. Czerwinski, Barry Goggin, Tzuling Cheng, Darryl D. Dixon, Hanbiao Yang, Stephen T. Schlachter, Xinlin Du, John A. Josey, Shanhai Xie, James P. Rizzi
Publikováno v:
Cancer research. 76(18)
More than 90% of clear cell renal cell carcinomas (ccRCC) exhibit inactivation of the von Hippel–Lindau (pVHL) tumor suppressor, establishing it as the major underlying cause of this malignancy. pVHL inactivation results in stabilization of the hyp
Autor:
Scott R. Whittemore, Melissa A. Maddie, Sujata Saraswat Ohri, Yongmei Zhao, Mengsheng S. Qiu, Michal Hetman
Publikováno v:
Glia. 59:1489-1502
Activation of the unfolded protein response (UPR) is involved in the pathogenesis of numerous CNS myelin abnormalities; yet, its direct role in traumatic spinal cord injury (SCI)-induced demyelination is not known. The UPR is an evolutionarily conser
Publikováno v:
Current Neurovascular Research. 6:124-131
Acute loss of spinal cord vascularity followed by an endogenous adaptive angiogenic response with concomitant microvascular dysfunction is a hallmark of traumatic spinal cord injury (SCI). Recently, the potent vasoactive factor vascular endothelial g
Autor:
Zhaodan Cao, Shanhai Xie, Christina Stevens, Tai W. Wong, Melissa A. Maddie, Guangzhou Han, Eli M. Wallace, Barry Goggin, John A. Josey
Publikováno v:
Cancer Research. 76:4022-4022
The majority of clear cell renal cell carcinoma (ccRCC) have deficiency in the gene encoding the von Hippel Landau (VHL) protein, as a result of DNA copy loss, non-sense mutations, and epigenetic silencing. Deficiency in VHL and its E3 ligase activit